| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Laboratory of Molecular Pharmacology, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, NIH, Bethesda, Maryland 20205 [N. W. G., L. C. E.], and Cancer Research Campaign Experimental Chemotherapy Group, Department of Pharmacy, University of Aston, Birmingham B4 7ET, England [J. A. H.]
Normal (IMR-90) and SV40-transformed (VA-13) human embryo cells were treated with 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (M&B 39565), and the effects of the drug on cell viability and cellular DNA integrity were studied. The effects of M&B 39565 were compared with one of its potential decomposition products 5-[3-(2-chloroethyl)triazen-1-yl]imidazole-4-carboxamide (MCTIC). M&B 39565 and MCTIC were 5- to 6-fold more toxic to VA-13 cells than to IMR-90 cells for drug concentrations which produced a 2-log cell kill, as measured by colony-forming assays. Using alkaline elution analysis, VA-13 cells exhibited concentration-dependent DNA interstrand cross-link formation. In IMR-90 cells, little or no interstrand cross-link formation was detected. The DNA interstrand cross-link formation in VA-13 cells was found to peak 12 hr after drug removal. A linear correlation between DNA interstrand cross-link formation and log cell kill was observed in VA-13 cells but not in IMR-90 cells. DNA-protein cross-link formation was found to be comparable in both cell lines for each drug, suggesting that drug penetration and intracellular drug reactivity were similar. Initial chemical decomposition studies suggest that both M&B 39565 and MCTIC may produce a chloroethyldiazo species. This species has been implicated in the formation of chloroethyl-DNA adducts which convert to DNA interstrand cross-links in mammalian cells treated with chloroethylnitrosoureas [Erickson et al., Nature (Lond.), 288: 727, 1980]. These data suggest that DNA interstrand cross-link formation may be a common mechanism for the in vitro cytotoxicity of M&B 39565 and MCTIC.
1 To whom requests for reprints should be addressed.
2 Present address: Section of Oncology, Loyola University, Stritch School of Medicine, Maywood, Illinois 60153.
Received 7/12/83. Accepted 1/27/84.
This article has been cited by other articles:
|
|
 |
|
  H. T. Jun, J. Sun, K. Rex, R. Radinsky, R. Kendall, A. Coxon, and T. L. Burgess AMG 102, A Fully Human Anti-Hepatocyte Growth Factor/Scatter Factor Neutralizing Antibody, Enhances the Efficacy of Temozolomide or Docetaxel in U-87 MG Cells and Xenografts Clin. Cancer Res., November 15, 2007; 13(22): 6735 - 6742. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Quinn, A. Desjardins, J. Weingart, H. Brem, M. E. Dolan, S. M. Delaney, J. Vredenburgh, J. Rich, A. H. Friedman, D. A. Reardon, et al. Phase I Trial of Temozolomide Plus O6-Benzylguanine for Patients With Recurrent or Progressive Malignant Glioma J. Clin. Oncol., October 1, 2005; 23(28): 7178 - 7187. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ostermann, C. Csajka, T. Buclin, S. Leyvraz, F. Lejeune, L. A. Decosterd, and R. Stupp Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Temozolomide in Malignant Glioma Patients Clin. Cancer Res., June 1, 2004; 10(11): 3728 - 3736. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. P. Spiro, L. Liu, S. Majka, J. Haaga, J. K. V. Willson, and S. L. Gerson Temozolomide: The Effect of Once- and Twice-a-Day Dosing on Tumor Tissue Levels of the DNA Repair Protein O6-Alkylguanine-DNA-Alkyltransferase Clin. Cancer Res., August 1, 2001; 7(8): 2309 - 2317. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. S. Friedman, T. Kerby, and H. Calvert Temozolomide and Treatment of Malignant Glioma Clin. Cancer Res., July 1, 2000; 6(7): 2585 - 2597. [Abstract] [Full Text]
|
|
|
|
|
|
L. A. Hammond, J. R. Eckardt, S. D. Baker, S. G. Eckhardt, M. Dugan, K. Forral, P. Reidenberg, P. Statkevich, G. R. Weiss, D. A. Rinaldi, et al. Phase I and Pharmacokinetic Study of Temozolomide on a Daily-for-5-Days Schedule in Patients With Advanced Solid Malignancies J. Clin. Oncol., August 1, 1999; 17(8): 2604 - 2604. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
